

# Richard T Silver

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/6474497/richard-t-silver-publications-by-year.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

146  
papers

8,626  
citations

33  
h-index

92  
g-index

156  
ext. papers

9,725  
ext. citations

3.6  
avg, IF

5.36  
L-index

#	Paper	IF	Citations
146	A Randomized, Phase 3, Trial of Interferon- $\beta$ Versus Hydroxyurea in Polycythemia Vera and Essential Thrombocythemia.. <i>Blood</i> , <b>2022</b> ,	2.2	6
145	Appropriate management of polycythaemia vera with cytoreductive drug therapy: European LeukemiaNet 2021 recommendations.. <i>Lancet Haematology</i> , <b>2022</b> , 9, e301-e311	14.6	6
144	Excess mortality in younger patients with myeloproliferative neoplasms.. <i>Leukemia and Lymphoma</i> , <b>2022</b> , 1-5	1.9	0
143	Hematopoietic Stem and Progenitor Cell Fitness As a Novel Prognostic and Monitoring Biomarker for JAK2 V617F Myeloproliferative Neoplasms (MPNs). <i>Blood</i> , <b>2021</b> , 138, 627-627	2.2	1
142	Normal Life Expectancy for Polycythemia Vera Patients Is Possible. <i>Blood</i> , <b>2021</b> , 138, 2575-2575	2.2	0
141	Interferon-alpha for treating polycythemia vera yields improved myelofibrosis-free and overall survival. <i>Leukemia</i> , <b>2021</b> , 35, 2592-2601	10.7	19
140	Response to pegylated interferon in a COVID-19-positive elderly woman with primary myelofibrosis treated with ruxolitinib. <i>Clinical Case Reports (discontinued)</i> , <b>2021</b> , 9, 2228-2235	0.7	3
139	Fedratinib Improves Myelofibrosis-related Symptoms and Health-related Quality of Life in Patients with Myelofibrosis Previously Treated with Ruxolitinib: Patient-reported Outcomes from the Phase II JAKARTA2 Trial. <i>HemaSphere</i> , <b>2021</b> , 5, e562	0.3	8
138	Assessment of Outcomes After Stopping Tyrosine Kinase Inhibitors Among Patients With Chronic Myeloid Leukemia: A Nonrandomized Clinical Trial. <i>JAMA Oncology</i> , <b>2021</b> , 7, 42-50	13.4	16
137	CML End Phase and Blast Crisis: Implications and Management. <i>Hematologic Malignancies</i> , <b>2021</b> , 179-196		0
136	Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: An updated analysis of the JAKARTA2 study using stringent criteria for ruxolitinib failure. <i>American Journal of Hematology</i> , <b>2020</b> , 95, 594-603	7.1	45
135	Symptom Burden and Quality of Life in High-Risk Essential Thrombocythemia and Polycythemia Vera Patients Receiving Hydroxyurea or Pegylated Interferon Alfa-2a: Results of Myeloproliferative Neoplasms Research Consortium (MPN-RC) 111 and 112 Trials. <i>Blood</i> , <b>2020</b> , 136, 19-21	2.2	
134	Interferon in Polycythemia Vera (PV) Yields Improved Myelofibrosis-Free and Overall Survival. <i>Blood</i> , <b>2020</b> , 136, 31-32	2.2	1
133	Myelofibrosis: best practices, controversies and 2019 update. <i>Expert Review of Hematology</i> , <b>2020</b> , 13, 71-84	2.8	0
132	Impact of bone marrow fibrosis grade in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: A study of the MYSEC group. <i>American Journal of Hematology</i> , <b>2020</b> , 95, E1-E3	7.1	3
131	Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea. <i>Blood</i> , <b>2019</b> , 134, 1498-1509	2.2	80
130	Second primary malignancies in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 2233 patients. <i>Cancer Medicine</i> , <b>2019</b> , 8, 4089-4092	4.8	10

129	Distinguishing essential thrombocythemia V617F from polycythemia vera: limitations of erythrocyte values. <i>Haematologica</i> , <b>2019</b> , 104, 2200-2205	6.6	8
128	Incremental Utility of Right Ventricular Dysfunction in Patients With Myeloproliferative Neoplasm-Associated Pulmonary Hypertension. <i>Journal of the American Society of Echocardiography</i> , <b>2019</b> , 32, 1574-1585	5.8	6
127	Fedratinib Induces Spleen Responses in Patients with Myeloproliferative Neoplasm-Associated Intermediate- or High-Risk Myelofibrosis (MF) Previously Exposed to Ruxolitinib (RUX), Regardless of Reason for Discontinuing RUX. <i>Blood</i> , <b>2019</b> , 134, 4165-4165	2.2	2
126	Fedratinib (FEDR) in myelofibrosis (MF) patients previously treated with ruxolitinib (RUX): A reanalysis of the JAKARTA-2 study.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 7057-7057	2.2	6
125	Health-Related Quality of Life (HRQoL) with Fedratinib, a Selective, Oral Inhibitor of Janus Kinase 2 (JAK2), in the Phase II JAKARTA2 Study in Patients with Intermediate- or High-Risk Myelofibrosis Previously Treated with Ruxolitinib. <i>Blood</i> , <b>2019</b> , 134, 2207-2207	2.2	
124	Patient-Reported Outcome Results from the U.S. Life after Stopping TKIs (LAST) Study in Patients with Chronic Myeloid Leukemia. <i>Blood</i> , <b>2019</b> , 134, 705-705	2.2	1
123	Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet. <i>Leukemia</i> , <b>2018</b> , 32, 1057-1069	10.7	263
122	Value of cytogenetic abnormalities in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study of the MYSEC project. <i>Haematologica</i> , <b>2018</b> , 103, e392-e394	6.6	20
121	Design and rationale for the life after stopping tyrosine kinase inhibitors (LAST) study, a prospective, single-group longitudinal study in patients with chronic myeloid leukemia. <i>BMC Cancer</i> , <b>2018</b> , 18, 359	4.8	11
120	Phenotype variability of patients with post polycythemia vera and post essential thrombocythemia myelofibrosis is associated with the time to progression from polycythemia vera and essential thrombocythemia. <i>Leukemia Research</i> , <b>2018</b> , 69, 100-102	2.7	5
119	Results of the Myeloproliferative Neoplasms - Research Consortium (MPN-RC) 112 Randomized Trial of Pegylated Interferon Alfa-2a (PEG) Versus Hydroxyurea (HU) Therapy for the Treatment of High Risk Polycythemia Vera (PV) and High Risk Essential Thrombocythemia (ET). <i>Blood</i> , <b>2018</b> , 132, 577-577	2.2	32
118	PRM-151 in Myelofibrosis: Efficacy and Safety in an Open Label Extension Study. <i>Blood</i> , <b>2018</b> , 132, 686-686		33
117	Gender effect on phenotype and genotype in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis: results from the MYSEC project. <i>Blood Cancer Journal</i> , <b>2018</b> , 8, 89	7	8
116	Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial. <i>Journal of Hematology and Oncology</i> , <b>2017</b> , 10, 55	22.4	208
115	The effect of initial molecular profile on response to recombinant interferon- $\beta$ treatment in early myelofibrosis. <i>Cancer</i> , <b>2017</b> , 123, 2680-2687	6.4	31
114	Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study. <i>Lancet Haematology</i> , <b>2017</b> , 4, e317-e324	14.6	148
113	Evaluation of serum erythropoietin values as defined by 2016 World Health Organization criteria for the diagnosis of polycythemia vera. <i>Leukemia and Lymphoma</i> , <b>2017</b> , 58, 2768-2769	1.9	5
112	Evaluation of bone marrow morphology is essential for assessing disease status in recombinant interferon $\beta$ treated polycythemia vera patients. <i>Haematologica</i> , <b>2017</b> , 102, e97-e99	6.6	6

111	European LeukemiaNet study on the reproducibility of bone marrow features in masked polycythemia vera and differentiation from essential thrombocythemia. <i>American Journal of Hematology</i> , <b>2017</b> , 92, 1062-1067	7.1	23
110	Management of CML-blast crisis. <i>Best Practice and Research in Clinical Haematology</i> , <b>2016</b> , 29, 295-307	4.2	47
109	Optimal therapy for polycythemia vera and essential thrombocythemia: Preferred use of interferon therapy based on phase 2 trials. <i>Hematology</i> , <b>2016</b> , 21, 387-91	2.2	10
108	Impact on MPN Symptoms and Quality of Life of Front Line Pegylated Interferon Alpha-2a Vs. Hydroxyurea in High Risk Polycythemia Vera and Essential Thrombocythemia: Interim Analysis Results of Myeloproliferative Disorders Research Consortium (MPD-RC) 112 Global Phase III Trial. <i>Blood</i> , <b>2016</b> , 128, 479-479	2.2	4
107	Interim Analysis of the Myeloproliferative Disorders Research Consortium (MPD-RC) 112 Global Phase III Trial of Front Line Pegylated Interferon Alpha-2a Vs. Hydroxyurea in High Risk Polycythemia Vera and Essential Thrombocythemia. <i>Blood</i> , <b>2016</b> , 128, 479-479	2.2	20
106	The Effect of Initial Molecular Profile on Response to Recombinant Interferon Alpha (rIFN $\alpha$ ) Treatment in Early Myelofibrosis. <i>Blood</i> , <b>2016</b> , 128, 944-944	2.2	3
105	Long-term outcomes of ruxolitinib (RUX) therapy in patients (pts) with myelofibrosis (MF): 5-year update from COMFORT-I.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 7012-7012	2.2	1
104	Evaluation of Bone Marrow morphology in Addition to JAK2 Allele Burden Is Essential for Assessing Disease Status in Recombinant Interferon Alpha-Treated Polycythemia Vera Patients. <i>Blood</i> , <b>2016</b> , 128, 5471-5471	2.2	
103	Chronic Myeloid Leukemia <b>2016</b> , 1-11		2
102	Allogeneic Transplantation for Patients With Advanced Myelofibrosis: Splenomegaly and High Serum LDH are Adverse Risk Factors for Successful Engraftment. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2016</b> , 16, 297-303	2	10
101	Strategies that delay or prevent the timely availability of affordable generic drugs in the United States. <i>Blood</i> , <b>2016</b> , 127, 1398-402	2.2	26
100	Management of chronic myeloid leukemia in blast crisis. <i>Annals of Hematology</i> , <b>2015</b> , 94 Suppl 2, S159-65		52
99	Recombinant interferon- $\alpha$ in myelofibrosis reduces bone marrow fibrosis, improves its morphology and is associated with clinical response. <i>Modern Pathology</i> , <b>2015</b> , 28, 1315-23	9.8	37
98	The hematocrit value in polycythemia vera: caveat utilitor. <i>Leukemia and Lymphoma</i> , <b>2015</b> , 56, 1540-1	1.9	9
97	Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I. <i>Haematologica</i> , <b>2015</b> , 100, 479-88	6.6	174
96	Interferon in polycythemia vera and related neoplasms. Can it become the treatment of choice without a randomized trial?. <i>Expert Review of Hematology</i> , <b>2015</b> , 8, 439-45	2.8	11
95	PRM-151 in Myelofibrosis: Durable Efficacy and Safety at 72 Weeks. <i>Blood</i> , <b>2015</b> , 126, 56-56	2.2	27
94	Life, genes, and death in Ph- MPNs. <i>Blood</i> , <b>2014</b> , 124, 2471-2	2.2	1

93	Arterial Thrombotic Complications Are Uncommon in Patients without Cardiovascular Risk Factors and Occur at Equivalent Rates in Chronic Myeloid Leukemia (CML) Patients Treated with Imatinib and Nilotinib. <i>Blood</i> , <b>2014</b> , 124, 1811-1811	2.2	2
92	Post-Polycythemia and Post-Thrombocytopenia Myelofibrosis Have Distinctive Clinical Phenotypes: An International Multicenter Study on 718 Patients. <i>Blood</i> , <b>2014</b> , 124, 1824-1824	2.2	1
91	A New International Multicenter-Based Model to Predict Survival in Myelofibrosis Secondary to Polycythemia and Thrombocytopenia: The Mysec Prognostic Model (MYSEC-PM). <i>Blood</i> , <b>2014</b> , 124, 1826-1826	2.2	2
90	Phase 2 Trial of PRM-151, an Anti-Fibrotic Agent, in Patients with Myelofibrosis: Stage 1 Results. <i>Blood</i> , <b>2014</b> , 124, 713-713	2.2	29
89	What Is the Most Cost-Effective Strategy for Treating Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia (CML) after Imatinib Loses Patent Exclusivity?. <i>Blood</i> , <b>2014</b> , 124, 738-738	2.2	5
88	Phase 2 trial of PRM-151, an antifibrotic agent, in patients with myelofibrosis: Stage 1 results.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 7114-7114	2.2	1
87	Are all interferons the same for therapy in polycythemia vera?. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2013</b> , 13 Suppl 2, S305-6	2	3
86	Ruxolitinib for myelofibrosis--an update of its clinical effects. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2013</b> , 13, 638-45	2	18
85	Interferon and the treatment of polycythemia vera, essential thrombocythemia and myelofibrosis. <i>Expert Review of Hematology</i> , <b>2013</b> , 6, 49-58	2.8	81
84	European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. <i>Blood</i> , <b>2013</b> , 122, 872-84	2.2	1413
83	Evaluation of WHO criteria for diagnosis of polycythemia vera: a prospective analysis. <i>Blood</i> , <b>2013</b> , 122, 1881-6	2.2	80
82	JAK2V617F allele burden is reduced by busulfan therapy: a new observation using an old drug. <i>Haematologica</i> , <b>2013</b> , 98, e135-7	6.6	27
81	Single agent bevacizumab for myelofibrosis: results of the Myeloproliferative Disorders Research Consortium Trial. <i>Haematologica</i> , <b>2013</b> , 98, 1421-3	6.6	10
80	Ruxolitinib Discontinuation In Patients With Myelofibrosis: An Analysis From Clinical Practice. <i>Blood</i> , <b>2013</b> , 122, 2833-2833	2.2	9
79	Long-Term Outcomes Of Ruxolitinib Therapy In Patients With Myelofibrosis: 3-Year Update From COMFORT-I. <i>Blood</i> , <b>2013</b> , 122, 396-396	2.2	18
78	Recombinant Interferon Alpha (rIFN) May Retard Progression Of Early Myelofibrosis By Reducing Splenomegaly and By Decreasing Marrow Fibrosis. <i>Blood</i> , <b>2013</b> , 122, 4053-4053	2.2	5
77	Efficacy and Safety Of Fedratinib (SAR302503/TG101348) In Patients With Intermediate- Or High-Risk Myelofibrosis (MF), Post-Polycythemia Vera (PV) MF, Or Post-Essential Thrombocythemia (ET) MF Previously Treated With Ruxolitinib: Interim Results From a Phase II Study (JAKARTA-2). <i>Blood</i> , <b>2013</b> , 122, 661-661	2.2	13
76	Treatment of polycythemia vera with imatinib mesylate. <i>Leukemia Research</i> , <b>2012</b> , 36, 156-62	2.7	9

75	Decrease in JAK2 V617F allele burden is not a prerequisite to clinical response in patients with polycythemia vera. <i>Haematologica</i> , <b>2012</b> , 97, 538-42	6.6	26
74	Long-Term Outcome of Ruxolitinib Treatment in Patients with Myelofibrosis: Durable Reductions in Spleen Volume, Improvements in Quality of Life, and Overall Survival Advantage in COMFORT-I. <i>Blood</i> , <b>2012</b> , 120, 800-800	2.2	8
73	Adverse events (AEs) and the return of myelofibrosis (MF)-related symptoms after interruption or discontinuation of ruxolitinib (RUX) therapy.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 6624-6624	2.2	2
72	Preliminary safety and efficacy of ruxolitinib in patients (pts) with primary and secondary myelofibrosis (MF) with platelet counts (PC) of 50-100x10 <sup>9</sup> /L.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 6630-6630	2.2	6
71	Monocytes Modulate Megakaryocyte-Mediated Fibrosis of Bone Marrow Stromal Cells in Vitro. <i>Blood</i> , <b>2012</b> , 120, 1759-1759	2.2	
70	Busulfan Induces Hematologic and Molecular Responses in Polycythemia Vera (PV) Refractory to Multiple Drugs. <i>Blood</i> , <b>2012</b> , 120, 5068-5068	2.2	
69	Recombinant interferon- $\alpha$ may retard progression of early primary myelofibrosis: a preliminary report. <i>Blood</i> , <b>2011</b> , 117, 6669-72	2.2	104
68	The treatment of essential thrombocytosis revisited. <i>Blood</i> , <b>2011</b> , 118, 1179-80; author reply 1180-1	2.2	3
67	Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. <i>Journal of Clinical Oncology</i> , <b>2011</b> , 29, 761-70	2.2	589
66	JAK2(V617F) allele burden in polycythemia vera correlates with grade of myelofibrosis, but is not substantially affected by therapy. <i>Leukemia Research</i> , <b>2011</b> , 35, 177-82	2.7	48
65	Predictive value of in vitro mutation data to guide second-generation tyrosine kinase inhibitor selection: ready for prime time?. <i>Oncologist</i> , <b>2011</b> , 16, 554-8	5.7	
64	Interferon alfa in the treatment of Philadelphia-negative chronic myeloproliferative neoplasms. <i>Journal of Clinical Oncology</i> , <b>2011</b> , 29, e564-5	2.2	19
63	Consistent Benefit of Ruxolitinib Over Placebo in Spleen Volume Reduction and Symptom Improvement Across Subgroups and Overall Survival Advantage: Results From COMFORT-I. <i>Blood</i> , <b>2011</b> , 118, 278-278	2.2	8
62	Prospective Evaluation of the World Health Organization Criteria for the Diagnosis of Polycythemia Vera,. <i>Blood</i> , <b>2011</b> , 118, 3837-3837	2.2	1
61	Associations Between Improvements in Myelofibrosis (MF) Symptoms and Quality of Life Measures with Splenomegaly Reduction in COMFORT-I: A Randomized, Double-Blind, Phase III Trial of the JAK1 and JAK2 Inhibitor Ruxolitinib Versus Placebo in Patients with MF,. <i>Blood</i> , <b>2011</b> , 118, 3842-3842	2.2	2
60	Clinical Burden and Progression of Myelofibrosis in a Controlled Study Population of Placebo-Treated Patients (COMFORT-I). <i>Blood</i> , <b>2011</b> , 118, 5146-5146	2.2	1
59	Jumping translocations of the long arms of chromosome 1 in myeloid malignancies is associated with a high risk of transformation to acute myeloid leukaemia. <i>British Journal of Haematology</i> , <b>2010</b> , 151, 288-91	4.5	18
58	Uncommon or delayed adverse events associated with imatinib treatment for chronic myeloid leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2010</b> , 10, 331-5	2	11

57	Allogeneic Stem Cell Transplantation for Patients with Chronic Myeloid Leukemia After Prior Treatment with Nilotinib or Dasatinib. <i>Blood</i> , <b>2010</b> , 116, 2348-2348	2.2	
56	In Vivo Imaging of Cerebral Circulation In Mouse Models of Polycythemia Vera. <i>Blood</i> , <b>2010</b> , 116, 4091-4091		
55	Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 6041-51	2.2	1019
54	The blast phase of chronic myeloid leukaemia. <i>Best Practice and Research in Clinical Haematology</i> , <b>2009</b> , 22, 387-94	4.2	21
53	The JAK2 46/1 Haplotype Predisposes to Myeloproliferative Neoplasms Characterized by Diverse Mutations.. <i>Blood</i> , <b>2009</b> , 114, 433-433	2.2	1
52	Tumor Necrosis Factor-Alpha (TNF) Expression Is Elevated in Myelo-Proliferative Neoplasms (MPN) and Modulated by Inhibition of JAK2 V617F.. <i>Blood</i> , <b>2009</b> , 114, 2917-2917	2.2	
51	A Novel in Vitro Model of Focal Fibrosis in Bone Marrow Stromal Co-Culture of CD34+ Cells From Patients with Idiopathic Myelofibrosis.. <i>Blood</i> , <b>2009</b> , 114, 2896-2896	2.2	
50	Jumping Translocations of the Long Arms of Chromosome 1 (1qJT) in Myeloproliferative Neoplasms (MPNs) and Myelodysplastic Syndromes (MDS) Are Associated with High Risk of Transformation to Acute Myelogenous Leukemia (AML).. <i>Blood</i> , <b>2009</b> , 114, 1567-1567	2.2	
49	The revised World Health Organization diagnostic criteria for polycythemia vera, essential thrombocytosis, and primary myelofibrosis: an alternative proposal. <i>Blood</i> , <b>2008</b> , 112, 231-9	2.2	137
48	A Phase I Study of XL019, a Selective JAK2 Inhibitor, in Patients with Polycythemia Vera. <i>Blood</i> , <b>2008</b> , 112, 2810-2810	2.2	10
47	Recombinant Interferon Alpha (rIFN $\alpha$ ) May Retard Progression of Early Primary Myelofibrosis (PM) by Reducing Splenomegaly and by Changing Marrow Morphology.. <i>Blood</i> , <b>2008</b> , 112, 1758-1758	2.2	1
46	Development of V617F JAK2 Associated Myeloproliferative Neoplasms Is a Non-Random Event That Is Strongly Dependent on JAK2 Haplotype. <i>Blood</i> , <b>2008</b> , 112, 173-173	2.2	
45	Update on the treatment of polycythemia vera with recombinant interferon alfa or imatinib mesylate. <i>Current Hematologic Malignancy Reports</i> , <b>2007</b> , 2, 43-6	4.4	2
44	Amplification refractory mutation system, a highly sensitive and simple polymerase chain reaction assay, for the detection of JAK2 V617F mutation in chronic myeloproliferative disorders. <i>Journal of Molecular Diagnostics</i> , <b>2007</b> , 9, 272-6	5.1	54
43	JAK2 V617F Mutational Load in Patients with Polycythemia Vera (PV) Measured by Peripheral Blood DNA Is Associated with Disease Severity.. <i>Blood</i> , <b>2007</b> , 110, 2530-2530	2.2	2
42	JAK2 Mutations Are Present in All Cases of Polycythemia Vera.. <i>Blood</i> , <b>2007</b> , 110, 4669-4669	2.2	
41	Long-term effects of the treatment of polycythemia vera with recombinant interferon-alpha. <i>Cancer</i> , <b>2006</b> , 107, 451-8	6.4	116
40	Treatment of polycythemia vera. <i>Seminars in Thrombosis and Hemostasis</i> , <b>2006</b> , 32, 437-42	5.3	7

39	Minimal molecular response in polycythemia vera patients treated with imatinib or interferon alpha. <i>Blood</i> , <b>2006</b> , 107, 3339-41	2.2	107
38	International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT). <i>Blood</i> , <b>2006</b> , 108, 1497-503	2.2	287
37	Chronic Myeloid Leukemia (CML): A Model Disease for Utilizing Evidence Based Guidelines in a Decade of Progress.. <i>Blood</i> , <b>2006</b> , 108, 3313-3313	2.2	
36	Correlation of Clinical and Molecular Response to Imatinib in Polycythemia Vera (PV) Patients with Bone Marrow Morphologic and Immunophenotypic Changes.. <i>Blood</i> , <b>2006</b> , 108, 4914-4914	2.2	
35	Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. <i>Blood</i> , <b>2005</b> , 106, 2162-8	2.2	706
34	The ABCCs of myelofibrosis. <i>Blood</i> , <b>2005</b> , 106, 2598-2599	2.2	
33	No Significant Molecular Response in Polycythemia Vera Patients Treated with Imatinib or Interferon alpha.. <i>Blood</i> , <b>2005</b> , 106, 373-373	2.2	
32	Treatment of polycythemia vera with recombinant interferon alpha (rIFNalpha) or imatinib mesylate. <i>Psychophysiology</i> , <b>2005</b> , 4, 235-7		5
31	Current treatment of myelofibrosis. <i>Clinical Advances in Hematology and Oncology</i> , <b>2005</b> , 3, 269-70	0.6	
30	Prognostic significance of additional cytogenetic abnormalities in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon- $\alpha$ A Cancer and Leukemia Group B study <b>2004</b> , 25, 143		1
29	Four Years of Follow-Up of 1027 Patients with Late Chronic Phase (L-CP), Accelerated Phase (AP), or Blast Crisis (BC) Chronic Myeloid Leukemia (CML) Treated with Imatinib in Three Large Phase II Trials.. <i>Blood</i> , <b>2004</b> , 104, 23-23	2.2	39
28	Imatinib Mesylate (GLEEVEC <sup>®</sup> ) Is Effective in the Treatment of Polycythemia Vera: A Multi-Institutional Clinical Trial.. <i>Blood</i> , <b>2004</b> , 104, 656-656	2.2	5
27	Pretreatment Cytogenetic Abnormalities in Polycythemia Vera (PV) Determines the Effectiveness of Imatinib : Studies from a Multi-Institutional Trial.. <i>Blood</i> , <b>2004</b> , 104, 2431-2431	2.2	
26	Chronic myeloid leukemia. <i>Hematology/Oncology Clinics of North America</i> , <b>2003</b> , 17, 1159-73, vi-vii	3.1	10
25	Treatment of the chronic phase of chronic myeloid leukemia with an intermittent schedule of recombinant interferon alfa-2b and cytarabine: results from CALGB study 9013. <i>Leukemia and Lymphoma</i> , <b>2003</b> , 44, 39-48	1.9	14
24	Correlation of three methods of measuring cytogenetic response in chronic myelocytic leukemia. <i>Cancer Genetics and Cytogenetics</i> , <b>2002</b> , 137, 79-84		20
23	Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. <i>Blood</i> , <b>2002</b> , 99, 1928-37	2.2	850
22	Risk factors for severe neuropsychiatric toxicity in patients receiving interferon alfa-2b and low-dose cytarabine for chronic myelogenous leukemia: analysis of Cancer and Leukemia Group B 9013. <i>Journal of Clinical Oncology</i> , <b>2000</b> , 18, 1301-8	2.2	49



21	Highly Sensitive Fluorescence In Situ Hybridization Method to Detect Double BCR/ABL Fusion and Monitor Response to Therapy in Chronic Myeloid Leukemia. <i>Blood</i> , <b>1998</b> , 91, 3357-3365	2.2	153
20	A Special Fluorescent In Situ Hybridization Technique to Study Peripheral Blood and Assess the Effectiveness of Interferon Therapy in Chronic Myeloid Leukemia. <i>Blood</i> , <b>1998</b> , 92, 2315-2321	2.2	66
19	Combination trial of subcutaneous recombinant alpha 2 b interferon and oral cyclophosphamide in follicular low-grade non-Hodgkin lymphoma. <i>Medical and Pediatric Oncology</i> , <b>1994</b> , 22, 228-35		9
18	Interferon-alpha 2b: a new treatment for polycythemia vera. <i>Annals of Internal Medicine</i> , <b>1993</b> , 119, 1091-82		48
17	Hodgkin disease survivors at increased risk for problems in psychosocial adaptation. The Cancer and Leukemia Group B. <i>Cancer</i> , <b>1992</b> , 70, 2214-24	6.4	128
16	Recombinant gamma-interferon has activity in chronic myeloid leukemia. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , <b>1990</b> , 13, 49-54	2.7	5
15	Spatial relationship of chromosomes 9 and 22 at metaphase in patients with chronic myelogenous leukemia (CML). <i>International Journal of Cancer</i> , <b>1988</b> , 41, 829-31	7.5	4
14	A comparative study of dibromomannitol and busulfan in the treatment of chronic myeloid leukemia. A study of cancer and leukemia group B. <i>Cancer</i> , <b>1987</b> , 60, 1442-8	6.4	8
13	HAC-Cytoxan (cyclophosphamide) chemotherapy for ovarian carcinoma. Alternating chemotherapy with intensification. <i>Cancer</i> , <b>1985</b> , 55, 2342-7	6.4	6
12	Unusual translocations involving chromosomes 12;22 and 9;12 in a case of chronic myelogenous leukemia. <i>Cancer Genetics and Cytogenetics</i> , <b>1985</b> , 14, 61-5		6
11	Treatment of advanced ovarian carcinoma with hexamethylmelamine, doxorubicin, and cis-platinum (HAC): results in both untreated and previously treated patients. <i>Medical and Pediatric Oncology</i> , <b>1984</b> , 12, 17-24		5
10	Administration of a complex chemotherapy regimen: inpatient versus outpatient treatment. <i>Medical and Pediatric Oncology</i> , <b>1983</b> , 11, 333-5		3
9	Clinical trial of VP 16--213 (NSC 141540) I.V. twice weekly in advanced neoplastic disease: a study by the Cancer and Leukemia Group B. <i>Cancer</i> , <b>1980</b> , 45, 232-5	6.4	64
8	Combination chemotherapy for non-Hodgkin lymphomas: a ten year follow-up study. <i>Medical and Pediatric Oncology</i> , <b>1979</b> , 6, 23-38		2
7	High dose methotrexate with citrovorum factor in adult resistant lymphoma. <i>Cancer</i> , <b>1977</b> , 40, 2823-8	6.4	14
6	The use of low-dose prednisone and melphalan in the treatment of poor-risk patients with multiple myeloma. <i>Medical and Pediatric Oncology</i> , <b>1975</b> , 1, 207-16		2
5	The Importance of Bone Marrow Biopsy in the Staging of Patients With Lymphosarcoma. <i>Blood</i> , <b>1973</b> , 41, 913-920	2.2	20
4	Characteristics of the Terminal Phase of Chronic Granulocytic Leukemia. <i>Blood</i> , <b>1968</b> , 32, 445-459	2.2	122

3	Arabinosyl Cytosine: A Useful Agent in the Treatment of Acute Leukemia in Adults. <i>Blood</i> , <b>1968</b> , 32, 507-523	441
2	Platelet Amino Acid Levels in Essential Thrombocytosis. <i>Blood</i> , <b>1966</b> , 27, 715-721	2.2 5
1	Use of Testosterone and Busulfan in the Treatment of Myelofibrosis with Myeloid Metaplasia. <i>Blood</i> , <b>1964</b> , 23, 341-353	2.2 25